Shattuck Labs, Inc. (STTK) Reports Phase I Results for SL-325 and Pipeline Developments
Shattuck Labs, Inc. has shared the Phase I results for its DR3 blocking antibody SL-325, along with updates on its ongoing pipeline.
Editorial Staff 5 days ago
#antibody therapy
1 article tagged with "antibody therapy"